Small inhibitor of Bcl-2, HA14-1, selectively enhanced the apoptotic effect of cisplatin by modulating Bcl-2 family members in MDA-MB-231 breast cancer cells [PDF]
, 2010 Inhibition or downregulation of Bcl-2 represents a new therapeutic approach to by-pass chemoresistance in cancer cells. Therefore, we explored the potential of this approach in breast cancer cells.
A Letai +34 more
core +1 more source
Implantation of paclitaxel-eluting stents in saphenous vein grafts: clinical and angiographic follow-up results from a multicentre study. [PDF]
, 2006 Objective: To define the clinical and angiographic follow-up results after implantation of paclitaxel-eluting stents (PESs) in stenotic saphenous vein grafts (SVGs). Design: Prospective multicentre study. Comparison with a control group.
Blindt, Ruediger +5 more
core +2 more sources
Combination of SAHA and Paclitaxel Induce Apoptosis of Human Cervical Cancer HeLa Cells
Zhongliu Fangzhi Yanjiu, 2018 Objective To investigate the inhibition effect of paclitaxel combined with SAHA on the proliferation of human cervical cancer HeLa cells in vitro and related mechanism.
ZHANG Lei +5 more
doaj +1 more source
The battle of “nano” paclitaxel
Advanced Drug Delivery Reviews, 2017 Paclitaxel (PTX) is one of the three most widely used chemotherapeutic agents, together with doxorubicin and cisplatin, and is first or second line treatment for several types of cancers. In 2000, Taxol, the conventional formulation of PTX, became the best-selling cancer drug of all time with annual sales of 1.6 billion.
Alexandros Marios Sofias +4 more
openaire +3 more sources
Low-Dose Continuous 5-Fluorouracil Combined with Leucovorin, nab-Paclitaxel, Oxaliplatin, and Bevacizumab for Patients with Advanced Pancreatic Cancer: A Retrospective Analysis. [PDF]
, 2018 BackgroundContinuous-infusion 5-fluorouracil (5FU) and calcium leucovorin plus nab-paclitaxel and oxaliplatin have been shown to be active in patients with pancreatic cancer.
Bedford, Rudolph +7 more
core +1 more source
Disruption of nNOS-NOS1AP protein-protein interactions suppresses neuropathic pain in mice [PDF]
, 2018 Elevated N-methyl-D-aspartate receptor (NMDAR) activity is linked to central sensitization and chronic pain. However, NMDAR antagonists display limited therapeutic potential because of their adverse side effects. Novel approaches targeting the NR2B-PSD95-
Chawla, Aarti +6 more
core +1 more source
Lapatinib and poziotinib overcome ABCB1-mediated paclitaxel resistance in ovarian cancer
PLoS ONE, 2021 Conventional frontline treatment for ovarian cancer consists of successive chemotherapy cycles of paclitaxel and platinum. Despite the initial favorable responses for most patients, chemotherapy resistance frequently leads to recurrent or refractory ...
J. Robert McCorkle +8 more
doaj +2 more sources
PEGylated graphene oxide for tumor-targeted delivery of paclitaxel. [PDF]
, 2015 AIM: The graphene oxide (GO) sheet has been considered one of the most promising carbon derivatives in the field of material science for the past few years and has shown excellent tumor-targeting ability, biocompatibility and low toxicity.
Abdelbary MA Elhissi +9 more
core +1 more source
Frontiers in Pharmacology, 2018 Objective: The aim of this study was to explore the tolerance, variability, and pharmacokinetics (PK) of albumin-bound paclitaxel (QL, HR, ZDTQ) among Chinese breast cancer patients.Methods: Three randomized, open-label, two-period crossover ...
Qingmei Li +8 more
doaj +1 more source
Molecular Oncology, EarlyView.This study used longitudinal transcriptomics and gene‐pattern classification to uncover patient‐specific mechanisms of chemotherapy resistance in breast cancer. Findings reveal preexisting drug‐tolerant states in primary tumors and diverse gene rewiring patterns across patients, converging on a few dysregulated functional modules. Despite receiving the
Maya Dadiani +14 more
wiley +1 more source